anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Treatment-naive high-risk DLBCL patients will be enrolled. R/R2-CHOP were allowed in cycle 1 due to poor physical condition or liver and renal failure caused by lymphoma progression. Patients achieving Complete Remission (CR) or Partial Remission (PR) after 2 cycles will receive another 2 cycles. Patients achieving CR or PR after 4 cycles will finish 6 cycles. Patients achieving CR after 6 cycles with double-hit/triple-hit/double-expression/median to high risk aaIPI will undergo Autologous Stem Cell Transplantation (ASCT). Other patients will be administered rituximab for another 2 cycles and then turn to follow-up. After completion of study treatment, patients are followed up every 3 months for 2 years, and then every 6 months for another 3 years. Patients achieving Stable Disease (SD) or PD (Progression Disease) after 2 or 4 cycles will quit the study. After 6 cycles, patients achieving SD or PD will quit the study and patients achieving PR will receive second-line therapy.
Adolescents will be assessed for a 48-70 hour period on the USS Virginia system. This time will include two dinner times, one with and one without announcement of carbohydrate content. This is a cross-over study, so all participants will also be tested on the Rocket AP system under the same conditions.
In this prospective, randomized, double blind study, the aim is to determine the efficacy of Linaclotide in relation to Senna in relieving the symptoms of chronic idiopathic constipation (CIC). Our hypothesis is that Senna is not inferior to Linaclotide in the treatment of CIC. Seventy patients aged 18-70 diagnosed with CIC and seen by a gastroenterologist affiliated with TriHealth or a patient of the Faculty Medical Center clinic will be included in the study. After enrollment, subjects will be randomized to receive either Linaclotide or Senna over a 12-week period after a 1 week wash-out period. During th study period, subjects will complete a log to record the number of daily bowel movements. The subjects will also complete 3 validated surveys on a weekly basis: Subject's Global Assessment SGA of Relief, Subject's Global Assessment SGA of Bowel Habit, and SGA of Satisfaction with their Bowel Habit. A research nurse will meet with subjects at the beginning of the study and then at 3 monthly visits to administer the study medication and distribute the surveys. The main outcomes measures are change in # of bowel movements and SGA survey scores.
BACKGROUND: An incomplete understanding of preterm birth is especially concerning for low-middle income countries, where preterm birth has poorer prognoses. While systemic proinflammatory processes are a reportedly normal component of gestation, excessive inflammation has been demonstrated as a risk factor for preterm birth. There is minimal research on the impact of excessive maternal inflammation in the first trimester on the risk of preterm birth in low-middle income countries specifically.
METHODS: Pregnant women were enrolled at the rural Bangladesh site of the National Institute of Child Health Global Network Maternal Newborn Health Registry. Serum samples were collected to measure concentrations of the inflammatory markers C-reactive protein (CRP) and Alpha-1-acid glycoprotein (AGP), and stool samples were collected and analyzed for enteropathogens. We examined associations of maternal markers in the first-trimester with preterm birth using logistic regression models. CRP and AGP were primarily modeled with a composite inflammation predictor.
RESULTS: Out of 376 singleton births analyzed, 12.5% were preterm. First trimester inflammation was observed in 58.8% of all births, and was significantly associated with increased odds of preterm birth (adjusted odds ratio [aOR] = 2.23; 95% confidence interval [CI]: 1.03, 5.16), independent of anemia. Maternal vitamin B12 insufficiency (aOR = 3.33; 95% CI: 1.29, 8.21) and maternal anemia (aOR = 2.56; 95% CI: 1.26, 5.17) were also associated with higher odds of preterm birth. Atypical enteropathogenic E. coli detection showed a significant association with elevated AGP levels and was significantly associated with preterm birth (odds ratio [OR] = 2.36; 95% CI: 1.21, 4.57), but not associated with CRP.
CONCLUSIONS: Inflammation, anemia, and vitamin B12 insufficiency in the first trimester were significantly associated with preterm birth in our cohort from rural Bangladesh. Inflammation and anemia were independent predictors of premature birth in this low-middle income setting where inflammation during gestation was widespread. Further research is needed to identify if infections such as enteropathogenic E. coli are a cause of inflammation in the first trimester, and if intervention for infection would decrease preterm birth.
This arm will be randomized to a discounted price (at baseline and every 6-months during the 3-year study) for solar electricity (in areas marker for solar grids by the Government of Rwanda) and LPG gas in a pay-as-you-go (PAYG) service model (i.e., pre-pay an affordable amount through mobile money, a common form of currency transactions in Rwanda). For example, this arm will be asked to cook as normal and decide whether or not to cook with the discounted LPG or their traditional stove (i.e., they will not be required to pay for LPG).
Suitable for high-risk group neuroblastoma treated by chemotherapy combined with surgery, radiotherapy and or hematopoietic stem cell transplantation patients with tumor residual or progression during treatment (refractory); Patients who relapse after initial treatment. Repeat every 3 weeks until tumor progression, patient withdrawal, or toxicity becomes intolerable, up to 8 procedures.
Participants will receive a 13-week supply of inert placebo capsules matched for polysaccharide content. Participants will take a total of two capsules each day.
A method of screening for pulmonary embolism uses gaseous phase polarized  129 Xe which is injected directly into the vasculature of a subject. The gaseous  129 Xe can be delivered in a controlled manner such that the gas substantially dissolves into the vasculature proximate to the injection site. Alternatively, the gas can be injected such that it remains as a gas in the bloodstream for a period of time (such as about 8-29 seconds). The injectable formulation of polarized  129 Xe gas is presented in small quantities of (preferably isotopically enriched) hyperpolarized  129 Xe and can provide high-quality vasculature MRI images or NMR spectroscopic signals with clinically useful signal resolution or intensity. One method injects the polarized  129 Xe as a gas into a vein and also directs another quantity of polarized gas into the subject via inhalation. In this embodiment, the perfusion uptake allows arterial signal information and the injection (venous side) allows venous signal information. The dual delivery is used to generate a combined introduction path with a more complete image signal of both the arterial and venous side of the pulmonary vasculature. In this NMR imaging method, the pulmonary embolism screening method can use the same NMR chest coil for the excitation and detection of the  129 Xe signals. The direct injection of small quantities of gas at particular sites along the vasculature targets specific target regions to provide increased signal intensity NMR images. The disclosure also includes related methods directed to other diagnostic vasculature regions physiological and conditions. Associated delivery and dispensing systems and methods, containers, and quantitative formulations of the polarized gas are also described.
<P>PROBLEM TO BE SOLVED: To provide a recombinant poxvirus expressing a gene product of Morbillivirus.  <P>SOLUTION: This recombinant poxvirus, such as vaccinia virus or canary pox virus, containing a foreign DNA from the Morbillivirus is provided. The foreign DNA is expressed in a host by production of a measles virus glycoprotein, or expressed in the host by production of at least two measles virus glycoproteins. Further, a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal which is inoculated with the vaccine is provided. Cross-protection of a dog against canine distemper is obtained by inoculating the dog with the recombinant poxvirus.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Despite the substantial work in cardiovascular pharmacogenomics published over the past decade, a fundamental gap remains in understanding whether the genomic diversity of Caribbean Hispanics accounts for high inter-individual variability of clinical outcomes to preventive dual antiplatelet therapy (DAPT) with clopidogrel. Caribbean Hispanics are disproportionately affected by cardio-metabolic disorders, but with a limited expectation of benefits from existing genomic-based algorithms. The investigators will focus on clopidogrel to develop urgently-needed genomic-driven prescription guidelines for this population. To this purpose, the investigators will implement a treatment algorithm to guide DAPT in Caribbean Hispanics and will create a repository of genomic DNAs and fully annotated clinical and genomic datasets from Caribbean Hispanics with cardiovascular diseases. This proposal will also take a novel approach to definitively assess the admixture component and is also highly practical for the development of a clinical decision support (CDS) tool. The investigators will test the following hypothesis: There are unknown genetic variants that uniquely contribute to clopidogrel responsiveness in Caribbean Hispanics to such extent that a developed CDS tool that incorporates personal ethno-specific genotypes and ex vivo pharmacodynamics (PD) testing will help enable more precise recommendations for optimizing medical outcomes to antiplatelet therapy in this population. To test this hypothesis we will work with the following aim: To implement a treatment algorithm based on ex vivo PD and genetic test results to guide DAPT in Caribbean Hispanics.

This clinical study will be conducted over 2-3 years in 250 naive cardiovascular patients to be treated with DAPT for secondary prevention of thromboembolic events (i.e., to be compared to another set of 250 clopidogrel-treated patients from a matched non-concurrent standard-of-care cohort). It is expected that this study advances the adoption of a Precision Medicine (PM) paradigm for the benefit of Hispanic patients. The richer genetic variance in Latinos is likely to contribute substantially to variability in response to drug treatments, a component that will be missed by traditional studies within homogeneous populations. This addressable oversight is of great concern since it will tend to exacerbate the healthcare disparity already experienced by Hispanic populations in the US. Hispanics have been largely excluded from Precision Medicine initiatives, which increase dramatically the disparities in translating benefits from new findings in pharmacogenomics to this medically underserved population, exacerbating the existing inequity in healthcare services. Accordingly, the proposed research will expand the current understanding of the pharmacogenomics of Clopidogrel. Advancing knowledge in the under-investigated area of pharmacogenetics in minority populations will generate results that apply to personalize DAPT in the wider population as it moves, inevitably, toward increasing heterogeneity through admixed genomes.
Subjects will receive GSK2798745 matching placebo tablets (two tablets on Day 1 followed by one tablet once daily for 6 days), via oral route (treatment period of total 7 days). After a washout period of 14 to 21 days, subjects will then receive 4.8 mg (two tablets of 2.4 mg) GSK2798745 on Day 1, followed by 2.4 mg GSK2798745 tablets once daily for 6 days via oral route (treatment period of total 7 days).
Group who has received an Educational Program (EP). The implementation of an EP based on meetings within the Department, coordinated by an outside tutor (outreach visit model). The EP content was defined beforehand by a Scientific Board, on the basis of evidence-based guidelines (EBGs) and an up-to-date literature review, but also with a specific focus on any departures from standard clinical practice recommendations (CPRs) identified at each IM department in phase 1.
The invention discloses a liniment with combination of Chinese medicine and western medicine for fire treatment and a preparation method thereof. The liniment comprises positive medicine and negative medicine; wherein the positive medicine is prepared withpseudo-ginseng, rhizoma zingiberis, camphor, cortex lycii radicis, earthworm, frankincense, rhizome of large-headed atractylodes, cayenne pepper, root of sheathed monkshood, salvia miltiorrhiza and scorpio in parts by weight; and the negative medicine is prepared pseudo-ginseng, snowflake flare, folium isatidis, rehmannia, cassia twig, root of sheathed monkshood, borneol, artificial feed musk and scorpio in parts by weight. In the preparation method, the positive medicine or the negative medicine is soaked in alcohol, so that Chinese medical components therein can be dissolved in the soaking alcohol to prepare the medicinal liquor liniment for fire treatment of cervical spondylosis, lumbar vertebra disease, arthralgia and pains caused by traumatic injury. Moreover, the western anti-inflammatory is added. When the liniment is used, the user can touch the burning medicinal liquor by hand and then immediately contact and massage the injured part, and then the muscle and pores can be expanded rapidly so that the efficacy can extend deep into the skin, meridians, collaterals and vertebral articulations. The liniment has the functions of clearing and activating the channels and collaterals, promoting the blood circulation and removing the blood stasis, and can rapidly ease the pain. Moreover, the liniment has the advantages of good effect, low cost, convenient use and no toxic or side effect.
This observational study included 80 consecutive patients presented by operable gastric cancer treated by D2 gastrectomy at Alexandria University hospital between January 2010 and January 2016, (Group I). Another 68 consecutive patients presented by operable gastric cancer treated by D1 gastrectomy earlier during the same period were included as a control (Group II). All patients had undergone preoperative gastroscopy and biopsy, chest and abdomen computed tomography (CT). All surgeries were performed by surgeons experienced in both D1 and D2 dissection and a standardized protocol for D1 and D2 gastrectomy was followed in all patients. The type of gastrectomy (distal or total) was done according to the site of the tumor; distal gastrectomy was done if there is a free safety margin of 4 cm beyond the proximal resection line otherwise total gastrectomy was done. Resection of the spleen and/or pancreatic tail were done if directly invaded by the primary tumor or metastatic LN. Patients with p T2 or greater, or with positive LN received adjuvant chemotherapy. Follow up was done as outpatient visits for average 5 years. Both groups were compared regarding postoperative morbidity and mortality, disease recurrence and survival rates.
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality in the United States. While increased physical activity can reduce this risk, less than half of adults in the United States meet the minimum recommendation guidelines for physical activity. Gamification, or the application of game design elements to non-game settings, has demonstrated promise in increasing physical activity when designed using insights from behavioral economics. However, the best way to design goal-setting within these interventions has not been well-examined. In this randomized controlled trial, the investigators will evaluate the effectiveness of four different goal-setting strategies within a gamification intervention to increase physical activity among adults with elevated risk for ASCVD. The trial will include a 2-week run-in period to estimate a baseline, followed by an 8-week introductory phase, an 8-week maintenance phase, and then after the intervention is completed an 8-week follow-up period.
<P>PROBLEM TO BE SOLVED: To provide a method for surely and effectively carrying out a handwork of medical chart management by simplifying it to prevent erroneous storage.  <P>SOLUTION: Ten frames for sticking a seal are provided along one side of a medical chart and numbering of 0-9 is in order printed before its each frame. Then, among color number seals on the market, a seal of the first place in carte number of the chart is stuck to the frame to which 10 place number of the same number is attached. This medical chart is stored by making the sticking seal to this side in a frame of the same number as lower two places of the card number of a shelf having 100 division frames suffixed by numbers of 00-99. Only seals of the same color are gathered at a position of the same height in each frame. When there is a difference in storage, that can be defined at first glance, normal storage is always kept and "surely effective medical chart control" is obtained. Further, arranging numbers of 100 places or over in each frame enables an approximate estimation of a position to be arranged in the carte frame to be obtained and makes its extraction very easy even when the medical chart reaches a large number.  <P>COPYRIGHT: (C)2007,JPO&INPIT
BACKGROUND: Controversies still exist regarding the mechanism formation of the blend sign, defined as hypodensity and hyperdensity regions, in Intracerebral Hemorrhage (ICH), and which region associated with bleeding remains unknown. Spot sign is an independent predictor of hematoma expansion (HE) and indicates persistent bleeding focus in the hematoma. Here, we sought to establish the relationship between the spot sign and the blend sign to gain insights into the formation of the blend sign.
METHODS: Patients were categorized based on the spot sign location within the blend sign in patients with ICH from 2018 to 2023. subjects with a spot sign in the hypodensity region of the blend sign (hypo-spot sign group); subjects with a spot sign in the hyperdensity region of the blend sign (hyper-spot sign group). Subsequently, patients were stratified into two groups based on the presence or absence of HE. Also, we analyzed the relationship between the spot sign and the blend sign, as well as the association between the blend sign and HE.
RESULTS: A total of 205 patients were included, including 190 patients (92.7%) who had the spot sign in the hyper-spot sign and 15 patients (7.3%) who had the spot sign in the hypo-spot sign. HE was observed in 60 patients (29.3%), 59 (98.3%) of whom had the spot sign detected in the hyper-spot sign, while only one (1.7%) had the spot sign in the hypo-spot sign. Univariate logistic regression analysis revealed that the hyper-spot sign group (6.305, 1.810-49.072; P < 0.05) was an independent predictor of HE.
CONCLUSION: The hyperdensity area of the blend sign may represent fresh bleeding in ICH rather than the hypodensity area.
PURPOSE: To obtain a low irritating cosmetic compsn. for skin conditioning. CONSTITUTION: This cosmetic compsn. contains an emulsible copolymer of a high percentage of a monoolefinic unsatd. carboxylic acid monomer with a low percentage of a long chain acrylate or methacrylate monomer, an anionic sulfosuccinate as an auxiliary surfactant and a medicinally allowable excipient. This compsn. is preferably in the form of transparent gel.
Advances in the understanding of cytokines have revolutionized mechanistic treatments for chronic inflammatory and autoimmune diseases, as exemplified by rheumatoid arthritis. We conducted a systematic literature review on the role of cytokines and chemokines in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN). Ovid Medline, EMBASE and Web of Science were searched until August 31, 2022 for human studies investigating cytokines levels in CIDP or MMN. Fifty-five articles on 1061 CIDP patients and 86 MMN patients were included, with a median of 18 patients per study (range 3-71). Studies differed in the inclusion criteria, type of assay, manufacturer, control subjects, and tested biological material. Only a minority of studies reported data on disease activity. Interleukin (IL)-6, IL-17, CXCL10, and tumor necrosis factor alpha (TNF-α), were elevated in CIDP compared to controls in most of the studies. IL-6 and TNF-α levels are also correlated with disability. In MMN patients, IL-1Ra was elevated in the majority of the reports. While acknowledging the challenges in comparing studies and the various limitations of the studies, including small patient numbers, particularly in MMN, our review suggests that IL-6, IL-17, CXCL10, and TNF-α might play a role in CIDP pathogenesis. Larger studies are needed in MMN.
<P>PROBLEM TO BE SOLVED: To provide a stable aqueous solution containing azulenes, improved in light stability, by preventing an insoluble substance from forming, and to provide a preparation enhanced in transferability of the azulenes and berberines to organismic tissue.  <P>SOLUTION: This aqueous solution is obtained by mixing (C) polyvinylpyrrolidone and/or chondroitins into an aqueous solution containing (A) the azulenes and (B) the berberines. The aqueous solution thus obtained is improved in the light stability, prevents the insoluble substance from forming, and therefore is excellent in long-term stability. Further, lipophilicity of the azulenes and the berberines which are pharmacologically active components is improved, so that the transferability thereof to the organismic tissue is enhanced. Therefore, the aqueous solution is useful as the external preparation, especially, as an ophthalmic preparation.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
279,575. Kornatzki, H. H. von. Aug. 7, 1926. Resin oils, extracting and purifying; soaps, compositions for making.-Oil of amber obtained by the dry distillation of amber is rectified by washing with 4-6 volumes of water. The extracted succinic acid is recrystallized, mixed with the rectified oil in the same proportion as in the crude oil, and the mixture used in the manufacture of medical preparations, massaging creams, tooth pastes, and cosmetics. For example, a soap for treating rheumatism is produced by adding 1 lb. of 95 per cent alcohol to 6 lb. of boiling fat and alkaline lye, and after saponification is complete stirring in 10 per cent of the rectified oil of amber and an aqueous solution of 1-2 per cent of the succinic acid, Massaging creams are obtained by adding the same proportions of the oil and acid to emulsified petrolatum and wool-fat. Bath salts result by crystallizing out a mixture of the succinic acid and the usual salts, drying, and mixing with the rectified oil. A tooth paste is made by mixing the oil and a powdered medicated soap, and stirring in the succinic acid, glycerine, chalk, magnesium carbonate, or other suitable abrasive.
PROBLEM TO BE SOLVED: To provide a lipid-formulated antineoplastic agent having new clinical usefulness.SOLUTION: The present invention relates to a liposomal antineoplastic agent composition. The liposomal antineoplastic agent used for the present invention includes, for example, camptothecin. The present invention further relates to a method of using such a composition in order to treat neoplasia. The present invention relates to a liposomal composition and a method of using such a composition in order to treat neoplasia and inhibit new vasculogenesis. The present invention provides a composition and a method useful for regulating plasma circulation half-life of an active agent (for example, topotecan). The liposome formulation increases clinical efficacy and decreases collateral toxicity. Further, the present invention provides a method and a liposome composition for treatment of neoplasia and inhibition of new vasculogenesis.